-
1
-
-
58749087713
-
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
-
Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, Kaplan RS, Maughan TS (2009) Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. Br J Cancer 100:251-258
-
(2009)
Br J Cancer
, vol.100
, pp. 251-258
-
-
Adams, R.A.1
Meade, A.M.2
Madi, A.3
Fisher, D.4
Kay, E.5
Kenny, S.6
Kaplan, R.S.7
Maughan, T.S.8
-
2
-
-
48749119784
-
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: A phase Ib/II study of the AIO GI Group
-
Arnold D, Hohler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Woll E, Herrmann T, Zubel A, Schmoll HJ (2008) Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: A phase Ib/II study of the AIO GI Group. Ann Oncol 19:1442-1449
-
(2008)
Ann Oncol
, vol.19
, pp. 1442-1449
-
-
Arnold, D.1
Hohler, T.2
Dittrich, C.3
Lordick, F.4
Seufferlein, T.5
Riemann, J.6
Woll, E.7
Herrmann, T.8
Zubel, A.9
Schmoll, H.J.10
-
3
-
-
79956310674
-
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
-
Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546
-
(2011)
Ann Oncol
, vol.22
, pp. 1535-1546
-
-
Bokemeyer, C.1
Bondarenko, I.2
Hartmann, J.T.3
De Braud, F.4
Schuch, G.5
Zubel, A.6
Celik, I.7
Schlichting, M.8
Koralewski, P.9
-
4
-
-
59949091448
-
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
-
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671
-
(2009)
J Clin Oncol
, vol.27
, pp. 663-671
-
-
Bokemeyer, C.1
Bondarenko, I.2
Makhson, A.3
Hartmann, J.T.4
Aparicio, J.5
De Braud, F.6
Donea, S.7
Ludwig, H.8
Schuch, G.9
Stroh, C.10
Loos, A.H.11
Zubel, A.12
Koralewski, P.13
-
5
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
Khayat, D.4
Bleiberg, H.5
Santoro, A.6
Bets, D.7
Mueser, M.8
Harstrick, A.9
Verslype, C.10
Chau, I.11
Van Cutsem, E.12
-
6
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-762
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
De Schutter, J.4
Biesmans, B.5
Fountzilas, G.6
Kalogeras, K.T.7
Kotoula, V.8
Papamichael, D.9
Laurent-Puig, P.10
Penault-Llorca, F.11
Rougier, P.12
Vincenzi, B.13
Santini, D.14
Tonini, G.15
Cappuzzo, F.16
Frattini, M.17
Molinari, F.18
Saletti, P.19
De Dosso, S.20
Martini, M.21
Bardelli, A.22
Siena, S.23
Sartore-Bianchi, A.24
Tabernero, J.25
Macarulla, T.26
Di Fiore, F.27
Gangloff, A.O.28
Ciardiello, F.29
Pfeiffer, P.30
Qvortrup, C.31
Hansen, T.P.32
Van Cutsem, E.33
Piessevaux, H.34
Lambrechts, D.35
Delorenzi, M.36
Tejpar, S.37
more..
-
7
-
-
78049341541
-
Association of KRAS P.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
-
De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820
-
(2010)
JAMA
, vol.304
, pp. 1812-1820
-
-
De Roock, W.1
Jonker, D.J.2
Di Nicolantonio, F.3
Sartore-Bianchi, A.4
Tu, D.5
Siena, S.6
Lamba, S.7
Arena, S.8
Frattini, M.9
Piessevaux, H.10
Van Cutsem, E.11
O'Callaghan, C.J.12
Khambata-Ford, S.13
Zalcberg, J.R.14
Simes, J.15
Karapetis, C.S.16
Bardelli, A.17
Tejpar, S.18
-
8
-
-
23644457632
-
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFRpositive adenocarcinoma
-
Delbaldo C, Pierga JY, Dieras V, Faivre S, Laurence V, Vedovato JC, Bonnay M, Mueser M, Nolting A, Kovar A, Raymond E (2005) Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFRpositive adenocarcinoma. Eur J Cancer 41:1739-1745
-
(2005)
Eur J Cancer
, vol.41
, pp. 1739-1745
-
-
Delbaldo, C.1
Pierga, J.Y.2
Dieras, V.3
Faivre, S.4
Laurence, V.5
Vedovato, J.C.6
Bonnay, M.7
Mueser, M.8
Nolting, A.9
Kovar, A.10
Raymond, E.11
-
10
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
Sartore-Bianchi, A.4
Arena, S.5
Saletti, P.6
De Dosso, S.7
Mazzucchelli, L.8
Frattini, M.9
Siena, S.10
Bardelli, A.11
-
11
-
-
78149250536
-
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
-
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705
-
(2010)
J Clin Oncol
, vol.28
, pp. 4697-4705
-
-
Douillard, J.Y.1
Siena, S.2
Cassidy, J.3
Tabernero, J.4
Burkes, R.5
Barugel, M.6
Humblet, Y.7
Bodoky, G.8
Cunningham, D.9
Jassem, J.10
Rivera, F.11
Kocakova, I.12
Ruff, P.13
Blasinska-Morawiec, M.14
Smakal, M.15
Canon, J.L.16
Rother, M.17
Oliner, K.S.18
Wolf, M.19
Gansert, J.20
more..
-
12
-
-
33644697486
-
Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma
-
Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Pollert P, Kohne CH (2006) Cetuximab and irinotecan/5-fluorouracil/ folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450-456
-
(2006)
Ann Oncol
, vol.17
, pp. 450-456
-
-
Folprecht, G.1
Lutz, M.P.2
Schoffski, P.3
Seufferlein, T.4
Nolting, A.5
Pollert, P.6
Kohne, C.H.7
-
13
-
-
0035447953
-
Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system
-
Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92:1331-1346
-
(2001)
Cancer
, vol.92
, pp. 1331-1346
-
-
Goldstein, N.S.1
Armin, M.2
-
14
-
-
68749119351
-
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
-
Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101:715-721
-
(2009)
Br J Cancer
, vol.101
, pp. 715-721
-
-
Loupakis, F.1
Ruzzo, A.2
Cremolini, C.3
Vincenzi, B.4
Salvatore, L.5
Santini, D.6
Masi, G.7
Stasi, I.8
Canestrari, E.9
Rulli, E.10
Floriani, I.11
Bencardino, K.12
Galluccio, N.13
Catalano, V.14
Tonini, G.15
Magnani, M.16
Fontanini, G.17
Basolo, F.18
Falcone, A.19
Graziano, F.20
more..
-
15
-
-
79959337678
-
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
-
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114
-
(2011)
Lancet
, vol.377
, pp. 2103-2114
-
-
Maughan, T.S.1
Adams, R.A.2
Smith, C.G.3
Meade, A.M.4
Seymour, M.T.5
Wilson, R.H.6
Idziaszczyk, S.7
Harris, R.8
Fisher, D.9
Kenny, S.L.10
Kay, E.11
Mitchell, J.K.12
Madi, A.13
Jasani, B.14
James, M.D.15
Bridgewater, J.16
Kennedy, M.J.17
Claes, B.18
Lambrechts, D.19
Kaplan, R.20
Cheadle, J.P.21
more..
-
16
-
-
0027415146
-
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer
-
Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H (1993) The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460
-
(1993)
Cancer
, vol.71
, pp. 2454-2460
-
-
Mayer, A.1
Takimoto, M.2
Fritz, E.3
Schellander, G.4
Kofler, K.5
Ludwig, H.6
-
17
-
-
79952768031
-
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-A randomized trial of the German AIO CRC study group
-
Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermuller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V (2011) Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC study group. J Clin Oncol 29:1050-1058
-
(2011)
J Clin Oncol
, vol.29
, pp. 1050-1058
-
-
Moosmann, N.1
Von Weikersthal, L.F.2
Vehling-Kaiser, U.3
Stauch, M.4
Hass, H.G.5
Dietzfelbinger, H.6
Oruzio, D.7
Klein, S.8
Zellmann, K.9
Decker, T.10
Schulze, M.11
Abenhardt, W.12
Puchtler, G.13
Kappauf, H.14
Mittermuller, J.15
Haberl, C.16
Schalhorn, A.17
Jung, A.18
Stintzing, S.19
Heinemann, V.20
more..
-
18
-
-
77954372574
-
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
-
Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Papai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC (2010) Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 16:3133-3143
-
(2010)
World J Gastroenterol
, vol.16
, pp. 3133-3143
-
-
Ocvirk, J.1
Brodowicz, T.2
Wrba, F.3
Ciuleanu, T.E.4
Kurteva, G.5
Beslija, S.6
Koza, I.7
Papai, Z.8
Messinger, D.9
Yilmaz, U.10
Faluhelyi, Z.11
Yalcin, S.12
Papamichael, D.13
Wenczl, M.14
Mrsic-Krmpotic, Z.15
Shacham-Shmueli, E.16
Vrbanec, D.17
Esser, R.18
Scheithauer, W.19
Zielinski, C.C.20
more..
-
19
-
-
79960892233
-
Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab
-
[abstr]
-
Tejpar S, Bokemeyer C, Celik I, Schlichting M, Sartorius U, Van Cutsem E (2011) Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 29:3511 [abstr]
-
(2011)
J Clin Oncol
, vol.29
, pp. 3511
-
-
Tejpar, S.1
Bokemeyer, C.2
Celik, I.3
Schlichting, M.4
Sartorius, U.5
Van Cutsem, E.6
-
20
-
-
79952153189
-
Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the nordic colorectal cancer biomodulation group
-
[abstr]
-
Tveit K, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Kure E, Ikdahl T, Skovlund E, Christoffersen T (2011) Randomized phase III study of 5-fluorouracil/folinate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. J Clin Oncol 29:365 [abstr]
-
(2011)
J Clin Oncol
, vol.29
, pp. 365
-
-
Tveit, K.1
Guren, T.2
Glimelius, B.3
Pfeiffer, P.4
Sorbye, H.5
Pyrhonen, S.6
Kure, E.7
Ikdahl, T.8
Skovlund, E.9
Christoffersen, T.10
-
21
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Kohne, C.H.2
Hitre, E.3
Zaluski, J.4
Chang Chien, C.R.5
Makhson, A.6
D'Haens, G.7
Pinter, T.8
Lim, R.9
Bodoky, G.10
Roh, J.K.11
Folprecht, G.12
Ruff, P.13
Stroh, C.14
Tejpar, S.15
Schlichting, M.16
Nippgen, J.17
Rougier, P.18
-
22
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019
-
(2011)
J Clin Oncol
, vol.29
, pp. 2011-2019
-
-
Van Cutsem, E.1
Kohne, C.H.2
Lang, I.3
Folprecht, G.4
Nowacki, M.P.5
Cascinu, S.6
Shchepotin, I.7
Maurel, J.8
Cunningham, D.9
Tejpar, S.10
Schlichting, M.11
Zubel, A.12
Celik, I.13
Rougier, P.14
Ciardiello, F.15
|